Stay updated with breaking news from Care Managers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years and ...
- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment - ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 genome-edited cell therapy, for the treatment of sickle cell disease (SCD) in patients ...
BOSTON - Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced today that the U.S. Food and Drug Administration has approved CASGEVY , a CRISPR/Cas9 genome-edited cell therapy, for...
Vertex and CRISPR Therapeutics have announced FDA approval for CASGEVY in treating sickle cell disease. Utilizing cutting edge CRISPR/Cas9 gene editing technology, a patient’s own genes are extracted, edited, and then reinserted to eliminate sickle cell in this new therapy.